Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
97 hedge funds and large institutions have $53.6M invested in Chinook Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 15 closing their positions.
2,100% more call options, than puts
Call options by funds: $66K | Put options by funds: $3K
100% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 21
5% less funds holding
Funds holding: 102 → 97 (-5)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
61% less capital invested
Capital invested by funds: $138M → $53.6M (-$84.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.85M |
| 2 |
Renaissance Technologies
New York
|
+$1.99M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$922K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$729K |
| 5 |
BlackRock
New York
|
+$670K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.25M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$834K |
| 4 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$673K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$557K |
KDNY Hedge Fund Activity: Q2 2019 in Review
97 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2019, worth a combined $53.6M — down 61% from $138M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KDNY and 12 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 42 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.85M. The largest seller was Fidelity Investments, cutting an estimated $2.54M.
- 97 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2019, down from 102 in Q1 2019.
- Funds reported $53.6M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2019, down 61% quarter-over-quarter.
- 12 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2019 and 15 closed out, a net change of -3 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2019 was JP Morgan Chase, an estimated $2.85M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2019 was Fidelity Investments, an estimated $2.54M sold.
Based on aggregated 13F filings for Q2 2019.